Loading quotes...
Forecast
| Buy |
4 |
| Hold |
0 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 27.69m | 4.08% |
| Gross profit | 16.93m | 3.64% |
| Net profit | -11.74m | 87.53% |
| EBITDA | -2.75m | 2,286.14% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €115.08m |
Number of shares | 38.11m |
52-week high/low | €6.54 - €0.00 |
| Dividends | No |
Beta | 0.28 |
P/E ratio | -0.24 |
PEG ratio | -0.01 |
P/B ratio | -0.24 |
P/S ratio | 0.16 |
Company profile
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
| Name | MDxHealth Aktie |
| CEO | Michael K. McGarrity |
| Headquarters | Herstal,
Belgium |
| Website | |
| IPO | 05/08/2008 |
| Employees | 312 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
London Stock Exchange | 0O8G.L |
Euronext | MDXH.BR |
London | 0O8G.L |
